ZyVersa Therapeutics, Inc.
Data quality: 83%
ZVSA
OTC
Manufacturing
Chemicals
$0.22
▲
$0.03
(15.79%)
Mkt Cap: 1.54 M
Price
$0.19
Mkt Cap
1.54 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Negative free cash flow of -5.11 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio0.08
Interest Coverage-49.67
Valuation
PE (TTM)
-0.06
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.1 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.3 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -24.95 M |
| ROE | N/A | ROA | -241.30% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -5.11 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.08 |
| Interest Coverage | -49.67 | Asset Turnover | N/A |
| Working Capital | -11.77 M | Tangible Book Value | -11.73 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.06 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -332.49% | ||
| Market Cap | 1.54 M | Enterprise Value | 1.54 M |
| Per Share | |||
| EPS (Diluted TTM) | -4.18 | Revenue / Share | N/A |
| FCF / Share | -0.63 | OCF / Share | -0.63 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 20.50% |
| SBC-Adj. FCF | -5.48 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -24.95 M | -9.41 M | -75,018.0 | -98.30 M | -240,700.0 |
| EPS (Diluted) | -4.18 | -8.48 | — | -108.97 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -25.49 M | -9.14 M | -820,068.0 | -107.75 M | -235,267.0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1.11 M | 1.78 M | 399,894.0 | 3.21 M | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | -513,209.0 | -269,856.0 | — | 457.0 | — |
| Income Tax | -851,659.0 | 6,745.0 | -745,050.0 | -9.46 M | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 347,901.0 | 20.60 M | 118.51 M | 22.11 M | 77.14 M |
| Total Liabilities | 12.73 M | 12.08 M | 18.51 M | 11.04 M | 3.65 M |
| Shareholders' Equity | -12.39 M | 8.52 M | 99.66 M | 11.07 M | -2.26 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | — | — | 928,389.0 |
| Current Assets | 347,901.0 | 1.72 M | 6.36 M | 3.35 M | 1.18 M |
| Current Liabilities | 12.73 M | 11.23 M | 8.19 M | 10.19 M | 276,835.0 |
{"event":"ticker_viewed","properties":{"ticker":"ZVSA","listing_kind":"stock","pathname":"/stocks/zvsa","exchange":"OTC","country":"US"}}